Skip to main content

Trade-Ideas LLC identified

Intersect ENT

(

XENT

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Intersect ENT as such a stock due to the following factors:

  • XENT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $4.5 million.
  • XENT has traded 160,628 shares today.
  • XENT is trading at 8.94 times the normal volume for the stock at this time of day.
  • XENT is trading at a new high 15.12% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in XENT with the Ticky from Trade-Ideas. See the FREE profile for XENT NOW at Trade-Ideas

More details on XENT:

Intersect ENT, Inc., a commercial stage drug-device company, provides therapeutic solutions for patients with ear, nose, and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. Currently there are 7 analysts that rate Intersect ENT a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Intersect ENT has been 367,900 shares per day over the past 30 days. Intersect ENT has a market cap of $383.0 million and is part of the health care sector and health services industry. Shares are down 38.6% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Intersect ENT as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, feeble growth in its earnings per share and generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed against the S&P 500 and did not exceed that of the Pharmaceuticals industry. The net income has significantly decreased by 54.0% when compared to the same quarter one year ago, falling from -$5.34 million to -$8.22 million.
  • Net operating cash flow has decreased to -$6.97 million or 25.08% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
  • INTERSECT ENT INC's earnings per share declined by 26.1% in the most recent quarter compared to the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, INTERSECT ENT INC reported poor results of -$1.01 versus -$0.75 in the prior year. This year, the market expects earnings to be in line with last year (-$1.01 versus -$1.01).
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 54.77%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 26.08% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, INTERSECT ENT INC's return on equity significantly trails that of both the industry average and the S&P 500.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.